Company Overview
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Why Investors Should Care
Generates a return on equity of 119.0%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $88.04M (+376.6% YoY); net profit $-784.96M.
- Trailing 12 Months Year-on-year growth — revenue +1125.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.48% |
| 1 Year: | 1,125.80% |
Stock Price Performance
| 1 Year: | +112.36% |
| 6 Months: | +31.07% |
| 3 Months: | +22.80% |
| 1 Month: | +18.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 119.0%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CYTK Cytokinetics, Incorporated R2K | 81.93 | -11.96 | $11.12B | 0.00% | -50.10% | 119.00% | 0.48% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.27M | 6.21M | 10.64M | 8.46M | 7.14M | 6.05M | 3.83M | 3.59M | 41.69M | 6.55M | 2.84M | 5.44M | 1.15M | 88.97M | 2.52M | 4.61M | 867.00K | 378.00K | 835.00K | 249.00K | 463.00K | 1.58M | 66.77M | 1.94M | 19.36M |
| Operating Income | -8.41M | -6.00M | - | -8.91M | -10.59M | -8.89M | - | -11.95M | -11.01M | 33.97M | - | -23.25M | -25.19M | -28.42M | - | -26.13M | -23.41M | -17.91M | -24.52M | -26.72M | -23.93M | -30.36M | -32.36M | 5.18M | -40.61M | -54.80M | -69.20M | -77.86M | -10.87M | -108.44M | -124.47M | -122.05M | -122.27M | -126.23M | -130.17M | -140.80M | -155.63M | -111.51M | -166.75M | -183.62M |
| Net Income | -8.37M | -5.97M | 8.44M | -8.87M | -10.55M | -8.85M | -9.23M | -12.46M | -11.61M | 33.36M | 7.16M | -25.87M | -29.08M | -32.36M | -40.48M | -30.28M | -27.52M | -22.02M | -29.37M | -32.11M | -29.57M | -39.41M | -40.78M | -3.17M | -47.10M | -61.55M | -76.09M | -89.44M | -19.82M | -142.31M | -131.29M | -128.64M | -129.42M | -135.64M | -143.32M | -160.54M | -161.38M | -134.37M | -306.18M | -206.03M |
| Diluted EPS | - | - | - | - | - | -0.23 | - | -0.31 | -0.29 | 0.77 | 0.16 | - | - | -0.60 | - | - | - | - | - | - | - | - | - | - | - | -0.86 | -0.95 | -1.05 | -0.23 | -1.52 | -1.38 | -1.34 | -1.35 | -1.33 | -1.31 | -1.36 | -1.36 | -1.12 | -2.55 | -1.67 |
| R&D Expense | 11.74M | 11.42M | - | 8.96M | 12.64M | 11.56M | - | 13.53M | 9.72M | 17.86M | - | 19.29M | 19.81M | 24.95M | - | 22.14M | 21.58M | 21.39M | 23.55M | 24.02M | 20.23M | 21.74M | 21.79M | 24.20M | 31.56M | 36.44M | 48.44M | 45.94M | 57.13M | 62.73M | 79.42M | 83.19M | 82.53M | 81.57M | 79.60M | 84.61M | 98.26M | 112.55M | 99.23M | 95.53M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 81.54M | 2.58M | 4.00M | 7.56M | 30.65M | 46.94M | 28.66M | 106.41M | 13.37M | 31.50M | 26.87M | 55.83M | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | 26.09M | -49.63M | -47.96M | -40.46M | -33.89M | -14.75M | -37.41M | 18.69M | -113.40M | -88.92M | -98.87M | -93.94M | -186.31M | -324.20M | -496.20M | -536.25M | -612.26M |
| Net Income | -7.34M | -13.08M | -15.87M | -23.08M | -32.69M | -37.20M | -42.25M | -57.12M | -48.89M | -56.37M | 24.54M | -49.29M | -47.86M | -40.37M | -33.72M | -14.65M | -37.50M | 16.45M | -127.79M | -106.29M | -121.69M | -127.29M | -215.31M | -388.95M | -526.24M | -589.53M | -784.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | 0.42 | -0.77 | -0.72 | - | - | -0.41 | -0.97 | 0.39 | -2.59 | - | - | -1.97 | -2.80 | -4.33 | -5.45 | -5.26 | -6.54 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 39.84M | 38.01M | 37.18M | 35.64M | 49.45M | 44.43M | 46.40M | 59.90M | 90.30M | 89.14M | 86.12M | 96.95M | 159.94M | 240.81M | 330.12M | 339.41M | 416.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | - | 77.99M | 52.77M | 77.55M | 83.19M | 132.97M | 115.24M | 170.14M | 294.81M | 211.18M | 289.81M | 533.80M | 841.32M | 1.01B | 824.32M | 1.40B | 1.42B |
| Total Equity | -2.00M | -9.12M | -21.82M | -37.35M | -60.59M | -92.03M | 107.56M | 73.56M | 106.31M | 99.92M | 49.77M | 101.43M | 70.52M | 48.18M | 70.08M | 54.44M | 92.06M | 68.59M | 94.36M | 109.84M | 25.93M | -10.94M | 113.38M | 243.86M | -107.90M | -386.32M | -135.37M | -659.62M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | 41.82M | 25.56M | 17.51M | 18.83M | 14.91M | 20.16M | 20.21M | 65.08M | 66.87M | 125.21M | 42.26M | 36.43M | 82.98M | 112.67M | 65.58M | 113.02M | 94.86M | 122.52M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 14.64M | 27.38M | 31.78M | 39.81M | 45.05M | 46.21M | 47.37M | 63.81M | 58.38M | 93.23M | 246.38M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 7.48M | 4.59M | 7.47M | 28.75M | 40.90M | 46.65M | 75.78M | 184.97M | 185.24M | 300.75M | 420.42M | 597.46M | 1.12B | 1.21B | 1.54B | 2.08B |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 7.32M | 4.59M | 7.11M | 26.70M | 23.86M | 31.65M | 33.26M | 32.44M | 22.19M | 26.02M | 31.20M | 71.86M | 84.62M | 102.68M | 179.67M | 202.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 8.42M | -44.83M | -45.59M | -33.44M | -7.72M | - | - | - | -101.76M | -101.22M | -90.91M | 8.94M | -142.52M | -299.52M | -414.33M | -395.89M | -510.01M |
| Investing Cash Flow | -53.48M | 34.24M | 25.30M | -28.82M | -1.52M | - | - | - | -65.83M | 5.13M | -74.71M | -196.51M | -147.78M | -262.13M | 239.25M | -553.10M | 16.67M |
| Financing Cash Flow | 28.81M | 2.55M | 21.61M | 58.33M | 14.49M | - | - | - | 225.92M | 13.13M | 159.79M | 234.12M | 319.98M | 516.17M | 221.32M | 930.61M | 524.46M |
| Capital Expenditure | -550.00K | -493.00K | -443.00K | -125.00K | -542.00K | -1.10M | -562.00K | -1.60M | -2.88M | -889.00K | -2.62M | -11.05M | -48.87M | -11.34M | -1.42M | -3.91M | -24.81M |
| Free Cash Flow | 7.87M | -45.32M | -46.04M | -33.56M | -8.26M | - | - | - | -104.64M | -102.10M | -93.53M | -2.11M | -191.39M | -310.85M | -415.75M | -399.80M | -534.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | 32.0% | -1,926.1% | -1,199.1% | -535.2% | -110.6% | -31.4% | -130.5% | 17.6% | -848.3% | -282.3% | -368.0% | -168.3% | -264.5% | -342.8% | -6,589.7% | -2,902.7% | -695.4% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | 30.1% | -1,912.6% | -1,196.5% | -534.1% | -110.0% | -31.2% | -130.9% | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6,988.6% | -3,191.1% | -891.6% |
| ROE % | 80.5% | 59.9% | 42.5% | 38.1% | 35.5% | -34.6% | -57.4% | -53.7% | -48.9% | -113.3% | 24.2% | -69.9% | -99.3% | -57.6% | -61.9% | -15.9% | -54.7% | 17.4% | -116.3% | -409.8% | 1,112.7% | -112.3% | -88.3% | 360.5% | 136.2% | 435.5% | 119.0% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | -70.2% | -99.5% | -57.4% | -60.0% | -13.5% | -44.8% | 13.7% | -43.2% | -47.0% | -37.5% | -18.7% | -24.2% | -34.9% | -68.8% | -43.9% | -50.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 14.08% | 17.52M | $1.49B |
| 2 | Blackrock Inc. | 13.30% | 16.55M | $1.41B |
| 3 | FMR, LLC | 8.62% | 10.72M | $913.67M |
| 4 | Wellington Management Group, LLP | 6.44% | 8.01M | $682.45M |
| 5 | Vanguard Portfolio Management LLC | 4.70% | 5.84M | $497.92M |
| 6 | State Street Corporation | 4.62% | 5.75M | $489.52M |
| 7 | Vanguard Capital Management LLC | 4.41% | 5.49M | $467.66M |
| 8 | Avoro Capital Advisors LLC | 2.68% | 3.33M | $284.02M |
| 9 | Geode Capital Management, LLC | 2.58% | 3.22M | $273.97M |
| 10 | Bank of America Corporation | 2.51% | 3.13M | $266.30M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CYTK
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPRTBzeWVfeUJtb3FEZDc0NHA2allSZlBidy1QMHQwaHJsQjlnQjVZMG9iNnQwNmxJRmd0U1ZSLXZoZnlkbkVwbVhuaFMxUEt2UWtIZTZwNTdkYXByUFF2SndiUW9zUHRya1h4NXhHMzVpZlpUQ1V4eHZBME43dmlDRHozTFctVXcxRFJldC…
Insider Sale: President & CEO of $CYTK Sells 10 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQcjFTVUY1Ulc4enJFQzE4dHFacXRFa1BHYjZmZXlIclZNeUtrdTRPY3U3TVN5Q2QzU29Ud1BrSFk2R3RqaUJ5Wmdzb1NVUjZ6cTJROEc3MUZKVFRUU0JRRmgtN1lGZG9STlBpVjVabnFHSF82VWw4VG5MTGFIYy1CNFBrUDJrdFlkRGw1N2…
Cytokinetics Inc (CYTK) CEO exercises options and sells 7,500 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQTU4yUFJVUGNzdHlsRlQyM25HUld1bU5kTERDT3JWcnVoal9EakMwdjMyaGZJTFdPWWF5QThhZl9FbkhfYjRVNHRtYVFEelhDOFlHREV4RzJLbWI5Rm5tZjBNd0V1VVJyYWtVSVduQkpwS2c3c1RJUWFMRlM3Z3hxYzY4eEZ2SDVQanFHbj…
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQLVpXdWp1VUhQdTJwbjB3Z2l5NlBtQXZ0Rk1IYkcwMlZGeDVIVXVxNlY4NjA0alJuRTNLZEdVVFQ2bFA5SlkxUmpWWXJHTW1XeUlZbC1aZnFsdG5KUW1aT1JlcFRHY3NrRWNZT1g0WkhKWEpfc2NMRDRkX3llRXhIT2ttbmYyZ0kwT18wc0…
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 27% Upside Potential - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQQkVIRHJURWlpTDhNbnJHVWRyTXVxdDRaQjZMSHBLdE9WZ01TZG41dUpRbjJTNU1RbzY2SGRxYnpjWU1NV1E2UnhETl9iNWEwSy1IalEyeFNqbVZkTTIxRk1sSm9EM180emJsTGRudTFycWFVc2lGUFhBc2FQMFhhR0lIZmZTVFNLSGY1YX…
Cytokinetics president & CEO Robert Blum sells $615,149 of stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQOE1GWTQ0aGJFYWI1eTdCWDczRVNCNmxYcFJTb0lDSnh6WkVVa3JaVURKZVdoekNiMjk1a1ZuU1VZdk02SjVVMmJSTGNLTWdRVm0waTRpRG1ocTBmcXkwS1p0N01LdjRaalAtX3RwOFNKb3J2cXFXZGo3WHNJYW5aYmtwS1ppQmVxZTJsbW…
CYTK — Frequently Asked Questions
What is the current share price of Cytokinetics, Incorporated (CYTK)?
As of 2026-07-14 21:23 PDT, Cytokinetics, Incorporated (CYTK) trades at $81.93 on NasdaqGS. Its 52-week range is $33.23 to $87.26.
What is the market capitalisation of CYTK?
Cytokinetics, Incorporated (CYTK) has a market capitalisation of $11.12B on NasdaqGS.
What is the P/E ratio of CYTK?
CYTK trades at a trailing price-to-earnings (P/E) ratio of -11.96. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -10.54.
What is the return on equity (ROE) of CYTK?
CYTK has a return on equity (ROE) of 119.00%. Its return on capital employed (ROCE) is -50.10%.
Is CYTK a good stock to buy?
This page provides a data-driven analysis of Cytokinetics, Incorporated (CYTK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.